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recently, the addition of a taxane such as docetaxel (or, less commonly, paclitaxel) to the PF regimen (a triple combination known as TPF) is emerging as a more effective and less toxic standard compared with PF for induction chemotherapy. 9 Recent studies suggest that there is a lower risk of distant metastases after induction chemotherapy than after primary radiotherapy or chemoradiotherapy. 10 Advances in the treatment of LA SCCHN over the past 30 years have provided some improvement in prognosis. 11, 12 Much of this improvement has been gained from the combination of different treatments rather than relying on a single treatment modality.
However, there is a continuing requirement for more effective therapies to prevent both relapses and metastases and to improve overall survival. Improved understanding of the pathogenesis of SCCHN has led to the introduction of molecularly targeted strategies.
The rationale behind these strategies is that by exploiting specific molecular modifications associated with cancer, transformed cells may be selectively targeted with less impact on healthy tissues. Such therapies are expected to have lower toxicity than chemotherapy, and may also have the potential to eliminate metastases that may not be eradicated with radiotherapy and/or surgery. 13, 14 Effective targeted therapy may specifically impede processes on which the cancer is dependent.
Epidermal growth factor receptor (EGFR) is a member of the human epidermal receptor (HER)/Erb-B family of receptor tyrosine kinases that transduce extracellular signals to intracellular responses. EGFR
has been implicated in the growth, survival and invasive potential of tumour cells and studies in SCCHN have shown that 80-100% of tumours and many cells adjacent to tumour tissue have abnormal levels of EGFR. 15 In one study, aberrant EGFR copy numbers were found in 32 of 134 tumours (24%) in patients with SCCHN and EGFR overexpression was associated with poor prognosis. 16 Therefore, much current research has been directed towards targeting abnormal EGFR activity in SCCHN. The EGFR inhibitors currently being studied include monoclonal antibodies, such as cetuximab and panitumumab and low-molecular-weight tyrosine kinase inhibitors, such as gefitinib and erlotinib. 1, 17 To date, small-scale studies investigating the use of gefitinib or erlotinib in combination with chemoradiotherapy in the treatment of LA SCCHN have shown some encouraging efficacy and safety findings. [18] [19] [20] [21] Newer dual tyrosine kinase inhibitors are also undergoing clinical trials in SCCHN, of which the furthest developed is lapatinib.
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Cetuximab
Cetuximab (Erbitux ® ) is an immunoglobulin G1 (IgG1) monoclonal antibody that inhibits ligand binding to the EGFR, 22 resulting in suppression of tumour growth, invasion, metastasis, DNA repair and angiogenesis. 23, 24 Moreover, cetuximab induces cell-mediated cytotoxicity. 25 It also enhances the activity of several chemotherapeutic agents, including cisplatin and 5-FU, and sensitises cancer cells to the effects of radiation therapy. [26] [27] [28] Currently cetuximab is the only targeted therapy approved for use in combination with radiotherapy in patients with LA SCCHN. Cetuximab has been approved for this indication in over 70 countries worldwide including, the US, EU, Russia, Australia, South Africa and countries in
Central and South America, the Middle East and South East Asia.
Clinical Development
A number of clinical trials have studied cetuximab in LA SCCHN. The use of cetuximab as an adjunct to radiotherapy was first investigated in 2001 in a phase I study 29 in which patients were given an initial dose of 100-500mg/m 2 followed by weekly doses of 100-250mg/m 2 . During a median 28-month follow-up period, 13 out of 15 patients showed a complete response and two had partial remissions. Fever, asthenia, transaminase elevation, nausea and skin toxicities (grade 1-2 in most patients) were the most frequent adverse events. It was concluded that cetuximab can be safely given with radiotherapy at an initial dose of 400-500mg/m 2 and a weekly dose of 250mg/m 2 .
The subsequent phase II and III studies investigating cetuximab in LA SCCHN can be divided into two general types: firstly, those using cetuximab concurrently with either radiotherapy or chemoradiotherapy; and secondly, those using cetuximab as part of induction or post-induction therapy regimens. An overview of the subsequent phase II and III studies both completed and ongoing is given in Table 1 .
Clinical Studies Including Cetuximab with Concurrent Radiotherapy or Chemoradiotherapy for LA SCCHN

Cetuximab with Radiotherapy
To date, the largest trial completed using cetuximab in LA SCCHN was a phase III study in which patients with locoregionally advanced unresectable cancers of the oropharynx, hypopharynx or pharynx received either radiotherapy alone or radiotherapy plus cetuximab at 73 treatment centres. 30 Patients were randomised to high-dose radiotherapy alone (≤76.8Gy total dose depending on site and regimen used) (213 patients) or high-dose radiotherapy plus weekly cetuximab (211 patients) at an initial dose of 400mg/m 2 , followed by weekly 250mg/m 2 for the duration of radiotherapy. Three-year data from this study showed that in the radiotherapy plus cetuximab group compared with the group that received radiotherapy alone, there was a 32% Cetuximab did not increase the incidence of toxic effects normally associated with radiotherapy in SCCHN. After three years of treatment, in the groups receiving radiotherapy alone and radiotherapy plus cetuximab, the more common severe (grade ≥3) adverse events included mucositis (52 and 56%, respectively), acneiform rash (1 and 17%, respectively), radiation dermatitis (18 and 23%, respectively), weight loss (7 and 11%, respectively), xerostomia (3 and 5%, respectively) and dysphagia (30 and 26%, respectively). Compared with the group receiving radiotherapy alone, grade ≥3 adverse events that were reported at a significantly higher frequency in the group receiving cetuximab plus radiotherapy were acneiform rash (1 versus 17%; p<0.001) and infusion reaction (0 versus 3%; p<0.001). A summary of the main findings from this study is given in Table 2 .
Recently, five-year data for the Bonner study were published and showed an overall survival of 45.6% in the combined treatment group
Cetuximab in the Treatment of Locally Advanced Head and Neck Cancer The pattern of adverse events after five years in the Bonner study was similar to the earlier findings. 31 The most commonly reported grade 3-4 adverse events in the radiotherapy alone and radiotherapy plus cetuximab groups were skin reaction (21.2 and 35.1%, respectively), mucositis/stomatitis (51.9 and 55.8%, respectively), dysphagia (29.7 and 26%, respectively), xerostomia (2.8 and 4.8%, respectively), acneiform rash (1.4 and 16.8%, respectively) and infusion reaction (0 and 2.9%, respectively).
Cetuximab with Chemoradiotherapy
An ongoing single-arm phase II study in Philadelphia, US, using cetuximab concurrently with chemoradiotherapy, is investigating the use of cetuximab added to a standard chemoradiotherapy regimen. 33 The study recruited 69 patients with LA SCCHN (mostly stage IV disease) who received initial cetuximab (400mg/m 2 ) followed by weekly doses (250mg/m 2 ) in combination with radiotherapy (70Gy) and cisplatin (75mg/m 2 ). Preliminary results demonstrated that 23% of patients experienced a complete response, 25% had a partial
Cetuximab in the Treatment of Locally Advanced Head and Neck Cancer response, 31% had stable disease and 5% showed disease progression. There was one case of grade 5 neutropenic fever that was attributed to treatment (although the publication did not specify which component of the treatment was considered to be the specific cause).
Among 65 evaluable patients in this study, 97% showed some form of grade >3 toxicity, including neutropenia (26%), fatigue (23%), acneiform rash (28%) and radiation dermatitis (15%). Other grade 3 or higher events included mucositis (54%) and hyponatraemia (20%).
Overall, these results indicated that weekly cetuximab with concurrent cisplatin and full-dose radiotherapy is a potential treatment for otherwise fit patients with unresectable LA SCCHN. The authors commented that longer follow-up is needed to determine locoregional control and survival end-points.
In another study, 34 22 patients with LA SCCHN at a treatment centre in New York, US, received concomitant boost radiotherapy (1.8Gy/day in weeks one to six with a 1.6Gy/day boost, to a total dose of 70Gy) with cisplatin 100mg/m 2 in weeks one and four and cetuximab 400mg/m 2 in week one, followed by 250mg/m 2 in weeks two to 10. The three-year overall survival rate, progression-free survival and locoregional control rates were 76, 56 and 71%, respectively. The toxicities were typical of those expected with definitive concurrent cisplatin and delayed, accelerated radiotherapy for SCCHN. 34 Common grade 3 or 4 toxicities included mucositis, skin toxicity, nausea, vomiting, fever, dehydration, metabolic abnormalities and constipation. This study, however, was stopped due to two patient deaths (pneumonia and unknown cause), and three events from which the patients recovered (myocardial infarction, bacteraemia and atrial fibrillation). There was no indication that cetuximab was the cause of these events.
A small single-arm phase II study in Italy showed the benefit of combining weekly cetuximab with a regimen of alternating radiotherapy and chemotherapy (AlteRCC trial). 35 Radiotherapy (2Gy/day to a total dose of 70Gy) was administered as a single daily 
Clinical Studies Using Cetuximab as Induction and/or Post-induction Therapy for LA SCCHN
Cetuximab in Post-induction Therapy Only
The Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab
After Induction Chemotherapy for Larynx Preservation (TREMPLIN) 30 and 2010. 31 study was a randomised phase II trial that was conducted in France. 
Quality of Life
LA SCCHN has an extremely deleterious effect on quality of life (QoL).
Symptoms occurring at this stage of disease can include difficulties swallowing and speaking, and surgical procedures to remove tumours in LA SCCHN can also be disfiguring. 42, 43 These symptoms often severely inhibit social interaction and diminish self-esteem. The treatments used for LA SCCHN can also negatively affect QoL since they can result in acute episodes of mucositis 44 and xerostomia. 45 Chemoradiotherapy has well-documented toxic effects including nausea and vomiting, diarrhoea, asthenia, hair loss and may necessitate the use of a feeding tube. These treatments therefore have the potential to substantially diminish QoL and may cause many patients to prematurely stop taking medication, resulting in treatment failure. 46, 47 A QoL analysis of a phase III trial comparing high-dose radiotherapy with or without concomitant cetuximab 48 concluded that the addition of cetuximab to radiotherapy significantly improved locoregional control and increased overall survival without having any significant effects on QoL. In this study, compliance with completing QoL questionnaires was high and the data are therefore considered to be reliable. 
